30
Participants
Start Date
March 31, 2012
Primary Completion Date
February 6, 2018
Study Completion Date
February 28, 2019
Hydroxychloroquine
Continuous oral administration (at 600 mg/d) will be initiated prior to the first dose (day -14) given 14 days prior to initiation of the first dose of IL-2 and then daily or twice a day throughout all three treatment courses.
IL-2
600,000 IU/kg IV bolus q 8 hrs x days 1-5 and 15-19 (maximum 28 doses - 14 per 5 day cycle) of each 84-day course
University of Pittsburgh Cancer Institute / UPMC CancerCenter, Pittsburgh
The Ohio State University Comprehensive Cancer Center, Columbus
Indiana University Simon Cancer Center, Indianapolis
Loyola University Chicago, Maywood
Providence Health & Services, Portland
Dana Farber Cancer Institute, Boston
Dartmouth-Hitchcock Medical Center, Hanover
Collaborators (1)
Prometheus Laboratories
INDUSTRY
Leonard Appleman
OTHER